好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Medical Aid in Dying: Perspective from a Tertiary Care Movement Center
Pain
P1 - Poster Session 1 (9:00 AM-5:00 PM)
443
To describe a tertiary-care movement disorders center’s experience with California’s medical-aid-in-dying (MAID) program.
Currently, nine states and the District of Columbia have laws that support some form of MAID.  California’s legislation was passed in 2016. To be eligible, patients must be at least 18 years-old, have a terminal diagnosis of an incurable disease confirmed by two physicians expected to result in death in 6 months, and have capacity to participate. Patients alone can request access to the program, must do so at two visits separated by at least fifteen days, and be able to self-administer medications. In California, patients with neurological diagnoses have been the second most frequent utilizers of the program following patients with cancer; however, current eligibility criteria may present several challenges for patients with neurodegenerative diseases.
We reviewed cases from the University of California San Diego Parkinson and Other Movement Disorders Center (UCSD-POMDC, which sees over 1,700 patients per year) who were enrolled in the MAID program from 2016 to present and describe their demographics and patient and provider experiences.

Thirteen patients were enrolled in the MAID, which is supported by a dedicated social worker in the medical oncology division (corticobasal syndrome: 6, progressive supranuclear palsy: 4, multiple systems atrophy: 2, Parkinson’s disease: 1). Patients had a desire to enter the program at early disease stages. At the six-month survival prognosis mark however, they often encountered common challenges in participating including dysphagia, inability to self-administer medications, or worsening cognitive impairment.
At our center a significant number of patients, predominantly with corticobasal syndrome, participated in the MAID over the last 5 years. MAID legislation is likely to expand in the future and patients with neurodegenerative diseases are likely to continue being a significant portion of participants. Tailoring legislation to accommodate patients with neurodegenerative disease is needed.
Authors/Disclosures
David G. Coughlin, MD (University of California San Diego)
PRESENTER 		Dr. Coughlin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for M3 Global Research. The institution of Dr. Coughlin has received research support from 好色先生. The institution of Dr. Coughlin has received research support from NIA. The institution of Dr. Coughlin has received research support from NINDS.
No disclosure on file
Robert Hess, MD Dr. Hess has nothing to disclose.
Kevin M. McGehrin, MD (UC San Diego Health) Dr. McGehrin has nothing to disclose.
No disclosure on file
Ece Bayram, MD, PhD The institution of Dr. Bayram has received research support from National Institute on Aging (K99AG073453). The institution of Dr. Bayram has received research support from Lewy Body Dementia Association. The institution of Dr. Bayram has received research support from National Institute of Neurological Disorders and Stroke.
Irene Litvan, MD, FAAN (UC San Diego Parkinson and Other Movement Disorder Center) Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aprinoia. Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Litvan has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology. Dr. Litvan has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Editor with Frontiers in Neurology.